Comparative Pharmacology
Head-to-head clinical analysis: N E E 1 35 21 versus YASMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: N E E 1 35 21 versus YASMIN.
N.E.E. 1/35 21 vs YASMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive: ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation; increases cervical mucus viscosity to impede sperm penetration; alters endometrial development to reduce implantation likelihood.
Combination of ethinyl estradiol and drospirenone suppresses gonadotropins, inhibiting ovulation. Drospirenone has antimineralocorticoid activity, reducing water retention, and antiandrogenic activity.
One tablet orally once daily for 21 days, followed by 7 days off.
One tablet (ethinyl estradiol 0.03 mg / drospirenone 3 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Norethindrone: terminal half-life 7-8 hours; Ethinyl estradiol: terminal half-life 12-14 hours (with enterohepatic recycling). Clinically, steady state achieved after 5-7 days.
Terminal elimination half-life is approximately 30 hours for drospirenone; steady-state concentration is achieved after 10 days of daily dosing.
Norethindrone (NET) and ethinyl estradiol (EE) are excreted primarily in urine (~50-60% as metabolites) and feces (~30-40% as metabolites); less than 1% excreted unchanged.
Approximately 40% renal and 60% fecal after oral administration; metabolites are excreted as glucuronide and sulfate conjugates.
Category C
Category C
Oral Contraceptive
Oral Contraceptive